Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2020

Secondary (Hypogonadotropic) Hypogonadism - Pipeline Review, H2 2020


latest Pharmaceutical and Healthcare disease pipeline guide Secondary Hypogonadism - Pipeline Review, H2 2020, provides an overview of the Secondary Hypogonadism (Womens and Male Health) pipeline landscape.

Hypogonadotropic hypogonadism (HH) is a form of hypogonadism that is due to a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes like gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH) and luteinizing hormone (LH). Symptoms include Lack of development at puberty, enlargement of the testes and penis, deepening of the voice, and facial hair. Treatment includes testosterone, estrogen and progesterone.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Secondary Hypogonadism - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Secondary Hypogonadism (Womens and Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Secondary Hypogonadism (Womens and Male Health) pipeline guide also reviews of key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Secondary Hypogonadism (Womens and Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Secondary Hypogonadism (Womens and Male Health).
- The pipeline guide reviews pipeline therapeutics for Secondary Hypogonadism (Womens and Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Secondary Hypogonadism (Womens and Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Secondary Hypogonadism (Womens and Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Secondary Hypogonadism (Womens and Male Health)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Secondary Hypogonadism (Womens and Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Secondary Hypogonadism (Womens and Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Secondary (Hypogonadotropic) Hypogonadism - Overview
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Secondary (Hypogonadotropic) Hypogonadism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Secondary (Hypogonadotropic) Hypogonadism - Companies Involved in Therapeutics Development
Allergan Ltd
Beijing Fogangren Bio-Pharm Tech Co Ltd
Diurnal Group Plc
IASO BioMed Inc
Marius Pharmaceuticals LLC
Merck & Co Inc
Mereo Biopharma Group Plc
NHTherapeutics Inc
Veru Inc
Secondary (Hypogonadotropic) Hypogonadism - Drug Profiles
corifollitropin alfa - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IAS-167A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leflutrozole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rifene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VERU-722 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products
Secondary (Hypogonadotropic) Hypogonadism - Product Development Milestones
Featured News & Press Releases
Jul 30, 2020: Diurnal Group announces positive DITEST regulatory meeting with US FDA
May 21, 2020: Marius Pharmaceuticals announces issuance of two key patents protecting its proprietary oral testosterone therapy
Jan 15, 2019: Mereo BioPharma: BGS-649 Phase 2b data to be Presented at ENDO 2019
Dec 17, 2018: Mereo BioPharma announces positive results from the safety extension study to the phase 2b clinical trial of BGS-649 for the treatment of hypogonadotropic hypogonadism in obese men
Sep 05, 2017: Completion of Patient Enrolment in Phase 2b dose-confirmation study of BGS-649 for the treatment of hypogonadotropic hypogonadism
Mar 07, 2017: Mereo BioPharma Group: Positive recommendation for BGS-649 Phase 2b trial following planned IDMC interim analysis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


List Of Tables


Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Allergan Ltd, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Beijing Fogangren Bio-Pharm Tech Co Ltd, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Diurnal Group Plc, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by IASO BioMed Inc, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Marius Pharmaceuticals LLC, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Merck & Co Inc, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by NHTherapeutics Inc, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Pipeline by Veru Inc, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Dormant Projects, H2 2020
Secondary (Hypogonadotropic) Hypogonadism - Discontinued Products, H2 2020


List Of Figures


Number of Products under Development for Secondary (Hypogonadotropic) Hypogonadism, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020


Secondary (Hypogonadotropic) Hypogonadism (Womens and Male Health) - Drugs in Development, 2021

Secondary (Hypogonadotropic) Hypogonadism (Womens and Male Health) - Drugs in Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Drugs In Development, 2021, provides

USD 2000 View Report

Secondary CNS Lymphoma (Oncology) - Drugs in Development, 2021

Secondary CNS Lymphoma (Oncology) - Drugs in Development, 2021Secondary CNS Lymphoma (Oncology) - Drugs in Development, 2021 provides an overview of the Secondary CNS Lymphoma pipeline landscape.The report provides comprehensive

USD 2000 View Report

Secondary (Hypogonadotropic) Hypogonadism (Womens and Male Health) - Drugs in Development, 2021

Secondary (Hypogonadotropic) Hypogonadism (Womens and Male Health) - Drugs in Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Secondary (Hypogonadotropic) Hypogonadism - Drugs In Development, 2021, provides

USD 2000 View Report

Secondary (Hypogonadotropic) Hypogonadism Disease - Global Clinical Trials Review, H2, 2020

Secondary (Hypogonadotropic) Hypogonadism Disease - Global Clinical Trials Review, H2, 2020This clinical trial report, Secondary (Hypogonadotropic) Hypogonadism Disease - Global Clinical Trials Review, H2, 2020 provides an overview of Secondary

USD 2500 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available